Neuren Pharmaceuticals (ASX:NEU) has initiated the development of NNZ-2591 to treat hypoxic-ischemic encephalopathy. …
Latest Video
New Stories
-
Island Pharmaceuticals secures key partnership with Texas Biomed
December 17, 2025 - - Australian Biotech -
Novartis names new Country President following leadership transition
December 16, 2025 - - Latest News -
Mayne Pharma opens expanded manufacturing facility after termination of takeover
December 16, 2025 - - Latest News -
Budget update includes impact of listings, but generally not much else
December 16, 2025 - - Latest News -
The UK reconfirms the direct impact of the transatlantic shift in medicine pricing
December 16, 2025 - - Latest News -
The industry is probably right to resist, it just needs to prepare for the response
December 16, 2025 - - Latest News -
Cynata completes patient enrolment in Phase 2 trial for aGvHD therapy
December 15, 2025 - - Australian Biotech